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OL-010 Sequential use of nitazoxanide (NTZ) as a
salvage therapy in patient with recurrent
mild to moderate Clostridium difﬁcile
infection (CDI): a prospective, open-label,
randomized clinical trial
P.P. Basu1,2 *, N.J. Shah2, N. Krishnaswamy2, R. Korapati2,
S. Tammisetti2, C.C. Tang2. 1Columbia University, New
York, 2North Shore University Hospital at Forest Hills, NY,
USA
Objectives: Vancomycin and metronidazole are currently
the recommend therapies for CDI. Treatment failure is due
to increasing antimicrobial resistance, insufﬁcient length
of therapy and suboptimal drug exposure. Recurrence is
estimated up to 20 50% in susceptible populations. We
utilize a novel sequential nitazoxanide treatment for 28
days for recurrent CDI.
Methods: Thirty (n = 30) patients (age:57.9±8.1 years; 13
non-hospital and 17 hospital acquired) were treated with
oral vancomycin or metronidazole for 14 days and had
recurrent CDI within 60 days post treatment. All patients had
abdominal pain, fever, diarrhea >3 times/day, leukocytes
>12,000, and positive stool toxin assay with Elisa A/B. All
were randomized into two groups: Group A (n = 15) patients
received nitazoxanide 500mg BID for 14 days, followed by
250mg BID for 7 days, followed by 125mg BID for 7 days;
Group B (n = 15) received vancomycin 250mg QID for 14
days, followed by 250mg BID for 7 days, followed by 125mg
BID for 7 days. Exclusion criteria: sepsis, toxic megacolon,
inﬂammatory bowel disease, Celiac disease, other colitidies,
renal sufﬁciency, probiotic use, immunocompromized state,
hemodialysis, or recent chemotherapy.
Results: Stool assay PCR for CDI was negative in 10/15
(66.7%) patients after sequential nitazoxanide treatment
and in 11/15 (73.3%) patients with sequential vancomycin
therapy. There was no signiﬁcant difference (p = 0.99,
Fisher’s exact test) in fecal eradication rate of CDI between
the two treatment groups. Side effects with nitazoxanide
treatment were minimal including nausea (n = 3), vomiting
(n = 1), constipation (n = 4), bloating (n = 2), loss of appetite
(n = 5), and yellow skin color (n = 3). This was comparable
to vancomycin.
Conclusion: This novel sequential therapy with nitazoxanide
shows a comparable cure rate to sequential oral
vancomycin treatment for recurrent CDI. Nitazoxanide has
an advantageous cost beneﬁt over oral vancomycin with
minimal side effects. A larger, double-blinded clinical trial
is warranted for validation.
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PL-003 Studies on constructing epidemic dynamic
system model and applying contact network
technique to novel inﬂuenza
S.-C. Ou1, H.-Y. Chung2, C.-Y. Chung2 *. 1Department of
Computer Science and Information Engineering, Leader
University, 2Department of Electrical Engineering, National
Central University, Taiwan
In the recent year, the Biomathematics has become the
main important trend of research direction which has
applied to the epidemic models of disease mechanism,
spreading regulation, and stategy of disease preventing in
the ﬁeld of medical and public health. Vector-borne disease
transmissions are inﬂuenced by vector population and
human population. In order to simulate the transmissions
of vector-borne diseases and discuss the related health
policies effects on vector-borne diseases, we combine the
multi-agent-based system, social network, mirror identity
concept, and compartmental model to develop an epidemic
simulation model. In the identity level, we use the
multi-agent-based system and the mirror identity concept
to describe identities with social network features such
as daily visits, long-distance movement, high degree of
clustering, low degree of separation, and local clustering.
In the vector level, we use compartment model concept
to describe the vector populations and the transmission
between populations.
The model will simulate a novel inﬂuenza outbreak and
other scenarios involving different seeding events and
interventions for example, antiviral prophylaxis, social
distancing policies or closures for schools and workplaces,
and control of inter-area movement.
The research will analyze the complex dynamic
mathematic model of novel inﬂuenza epidemic and
determine its stability property by using the popular
Matlab/Simulinksoftware and relative software packages.
Facing to the currently novel inﬂuenza epidemic situation,
in this project we will investgate the development of novel
inﬂuenza and its developing trend throught constructing the
dynamic biomathematics system model of novel inﬂuenza.
We will try to constructing epidemic dynamic system model
and applying contact network technique to novel Inﬂuenza
to ﬁnd the quarantining parameters which are the most
important factors to control epidemic situation, as shown
in the examples. The results of experiment by numerical
analysis may offer some prevention with reference to
control epidemic situation of novel inﬂuenza.
OL-011 Clinical features and 3-month follow up study of
pneumonia caused by inﬂuenza A (H1N1) virus
in Beijing, China
L. Bai1 *, L. Gu1, B. Cao1, X.-L. Zhai2, M. Lu3, L. Zhang2,
Z.-F. Gao4, K.-W. Huang5, Y.-M. Liu1, S.-F. Song1, L. Wu1,
Y.-D. Yin1, C. Wang1. 1Department of Infectious Diseases
and Clinical Microbiology, Beijing Chao-Yang Hospital,
Capital Medical University, Beijing, 2Department of
Radiology, Beijing Chao-Yang Hospital, Medical University,
3Department of Pathology, Beijng University Capital,
4Department of Pathology, Beijng University Capital,
5Department of Respiratory and Intensive Care Medicine,
Beijing Institute of Respiratory Medicine, Beijing Chao-Yang
Hospital, Capital Medical University, Beijing, China
Background: Data of symptomatic and radiographic changes
in patients with 2009 pandemic inﬂuenza A (H1N1)
pneumonia in the convalescent periods was not available.
Methods: During October 26, 2009 and January 23, 2010, 71
cases with pneumonia caused by 2009 pandemic inﬂuenza A
(H1N1) were observed during 3-month follow-up, clinical
data were collected, high-resolution chest CT and lung
function tests were performed.
Results: Of the 71 cases, median age was 41 (IQR 28
to 56) years; 63.4% were male, 54.9% had at least one
underlying medical condition. 68 patients received antiviral
treatment, and 33 received intravenous corticosteroids.
36 of 71 patients developed acute respiratory distress
syndrome during the illness. Of 25 patients who were
treated with mechanical ventilation, 14 survived with
noninvasive ventilation. 9 patients died at a median of
16 (IQR 10 to 24) days after onset of illness. Two risk
factors were identiﬁed to be independently associated with
death analyzed by multivariate Cox regression: progressing
dyspnea after resolution of fever (relative risk, 5.667;
S6 Abstracts, 4th DICID
95%CI, 1.312 to 24.475; P= 0.020) and higher APACHE II
score on presentation (relative risk for each point, 1.329;
95%CI, 1.156 to 1.527; P< 0.001). At 3-month follow-up of
H1N1 pneumonia survivors, ground-glass opacities (GGO)
still existed in most patients (82%) with lesser extent,
and lung function tests revealed that decreased diffusing
capacity for carbon monoxide of mild degree was the most
common (60%) abnormality.
Conclusions: GGO and decreased diffusing capacity were
the main abnormalities at 3-month follow-up of H1N1
pneumonia survivors.
OL-012 The comparison of glucocorticosteroid treating
critically ill patients with pandemic 2009
inﬂuenza A (H1N1) virus infection in Beijing
R.M. Jiang1 *, X.J. Wang1, X.W. Li1, L.M. Guo1, G.F. Wang2,
X.Y. Xu2, Z.Q. Gao3, Z.H. Tong4, G.Q. Xie5, X.M. Xi6,
Z.R. Liu7. 1Beijing Ditan Hospital, 2Peking University First
Hospital, 3Peking University Second Hospital, 4Beijng
Chaoyang Hospital, 5Clinical Research Institute of Peking
University, 6Beijing Fuxing Hospital, 7Peking University
Sixth Hospital, China
To explore the effect of glucocorticiod therapy in critically
ill patients, we describe the clinical characteristics of 55
patients with 2009 H1N1 inﬂuenza hospitalized in Beijing
Ditan Hospital from 3 Oct 2009 to 23 Dec 2009, comparing
the disparity in baseline characteristics and outcomes.
The primary outcome measure was mortality. Secondary
outcomes included duration of mechanical ventilation and
ICU stay as well as the secondary infection. RESULTS The
condition of patients who were received glucocorticosteroid
was more severe than those who were not, which was
presented at the rate of bloody sputum occurred and
ARDS developed. After given glucocorticosteroid, there were
no differences in the duration of hospitalization and ICU
stay and morality rate. Four variables (underlying medical
condition, hemoptysis sputum, ARDS, secondary bacterial
infection and glucocorticosteroid therapy) included in the
Cox regression model for analysis of risk factors. It showed
that the treatment of glucocorticosteroid was identiﬁed
as a possible protective factor for death that was about
0.242 times as those of unused steroids (OR, 0.242, 95%
CI: 0.064 0.920, P value was 0.037). Besides this, using
glucocorticosteroid can decrease the count of CD4+ and
CD8+ T lymphocyte, increasing the chance of bacterial
infection (P< 0.05).
OL-013 Detection of antibodies against avian inﬂuenza
in humans and conﬁrmation of avian inﬂuenza
virus in animals and the environment in the
region of positive avian inﬂuenza in human and
in poultry
A.E.T.H. Wahyuni1 *, W. Asmara1, M. Hariyadi1, K. Putri2,
S. Budhi3, C. Rangga Tabbu4, A. Setyawati5. 1Department
of Microbiology, Faculty of Veterinary Medicine, University
of Gadjah Mada, 2Department of Public Health, Faculty
of Veterinary Medicine, University of Gadjah Mada,
3Department of Clinic, Faculty of Veterinary Medicine,
University of Gadjah Mada, 4Department of Pathology,
Faculty of Vetrinary Medicine, University of Gadjah Mada,
5Sardjito Hospital, Faculty of Medicine, University of
Gadjah Mada, Indonesia
Background: Since the outbreak of highly pathogenic avian
inﬂuenza (HPAI) H5N1in Indonesia in 2003, almost all of 33
provinces of Indonesia are now becoming an endemic area,
and infection of AI in Indonesia is great concern due to
the high human case fatality rate and the threat of new
inﬂuenza pandemic. This study aimed to detect antibodies
against avian inﬂuenza in humans by hemagglutination
inhibition test (HI) and conﬁrmed of avian inﬂuenza virus
(AIV) in Animals by Polymerase Chain Reaction (PCR) in the
positive region of avian inﬂuenza in humans and in poultry.
Method: This study was conducted by collecting blood from
21 people who live around the house the victim died of bird
ﬂu and 18 blood of people who treat and handle victims
during the hospital including doctors. Blood serum was then
sent to the Research and Development for the examination
of antibody titer against H5 inﬂuenza virus. As many as eight
of the avian cloaca swab (a kampong chickens, Muscovy
duck tail 3, 4 birds), Five nasal swab (3 dogs, 2 cats) and
two samples (stool pigeon stuck in cages and ﬁsh pond
water which has that ﬁsh fed chicken carcasses who suspect
died because of avian inﬂuenza virus detection by PCR in
the microbiology laboratory Faculty of Veterinary Medicine,
UGM.
Result: Results from this study show that all human blood
serum of whether they live in around the house of victims
and those who care for at the hospital all negative. However,
all birds, cats and the environment all the AI H5 virus was
detected.
Conclusion: This research can be concluded that antibodies
against AIV of H5 is not found in the blood serum of humans
who had contact with the victim. Almost all animals and
the environment detected the presence of H5 AIV.
OL-014 Research on expulsion law of inﬂuenza A (H1N1)
virus and antiviral therapy
Y.X. Liu1 *, L.N. Liu2, B.P. Zhou1, H.J. Li1, J.M. Li1,
G.L. Yang1, X.C. Chen1. 1Shenzhen Third People’s Hospital,
2Chuanshan College of University of South China, China
Background: Current characteristics of A type inﬂuenza
H1N1 inﬂuenza virus, antiviral drug resistance, interaction
mechanism between virus and immune system are not clear.
Here in the present research, we investigate the A (H1N1)
inﬂuenza patients whose viral expulsion law and antiviral
effecacy in Shenzhen city in 2009.
Methods: Begin the antiviral therapy with Oseltamivir (I) or
the Chinese medicine (II) or Oseltamivir combined with the
Chinese medicine (III) respectively for 5 days immediately
after testing A (H1N1) ﬂu virus nucleic acid (RT-PCR) positive
in 75 patients. T lymphocyte subpopulation and IL-17 were
identiﬁed by ﬂow cytometry.
Results: 78.7% (59/75) of patients whose mean age was
(22.25±10.38) years old virus nucleic acid turned negative
in 7 days of duration. 21.3% (16/75) of patients whose
mean age was (17.16±13.66) years old virus were still
positive after 7 days of duration. Analysis of humoral
and cellular immune function in 56 patients showed down
IL-17 expression compared with seasonal ﬂu and health
control (P < 0.01). 10 cases whose virus persistence more
than 7 days showed down IL-17 expression (1.91±0.80)
compared with that of 46 cases whose virus turn negative in
7 days (3.05±1.59) (P < 0.05). Likewise, the former showed
signiﬁcant low IL-17 expression compared with seasonal ﬂu
(P < 0.01) and health control (P < 0.001). It took smaller
hours of getting normathermia after treatment in group III
than that of the other two groups (P < 0.05).
Conclusion: IL-17 and age are possibly interrelate with
A (H1N1) ﬂu virus infection and virus persistence.
Oseltamivir combined traditional Chinese medicine
treatment shows its unique advantage in antiviral efﬁcacy
and to alleviate the symptoms.
